by lythamcorp | Apr 1, 2026 | Arianne Phosphate News
DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQB (USA)SAGUENAY, QC, April 1, 2026 /CNW/ – Arianne Phosphate Inc. (the “Company” or “Arianne”) (TSXV: DAN) (OTCQB: DRRSF) (FRANKFURT: JE9N), a development-stage phosphate mining company,...
by lythamcorp | Apr 1, 2026 | IPM, IPM News, Technology
IPM to offer “MASORI GO” to clients to facilitate seamless integration with workflows and tools to accelerate development and engagement JERICHO, NY / ACCESS Newswire / April 1, 2026 / Intelligent Protection Management Corp. (“IPM,”...
by lythamcorp | Mar 31, 2026 | Cadrenal Therapeutics, Cadrenal Therapeutics News, Healthcare
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunityPONTE VEDRA, Fla., March 31, 2026 (GLOBE NEWSWIRE) —...
by lythamcorp | Mar 31, 2026 | PolyPid, PolyPid News
PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026 U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD)...
by lythamcorp | Mar 30, 2026 | Reviva Pharma News
– Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – – Current data package highlights well-tolerated long-term safety profile,...